Meet DIMA BIOTECH at ChAbS 2026

Many important druggable targets are multi-pass transmembrane proteins, including GPCRs, ion channels, and Claudins. Due to the extreme challenges in obtaining purified, functional proteins, only a limited number of these targets have successfully led to FDA-approved antibody drugs.

To address these challenges, DIMA BIOTECH has systematically optimized each step of the antibody discovery process. In this poster, we demonstrate how integrated platforms—including Nanodisc technologies (Syndisc™, PeptiNanodisc™), Single B enrichment, and DiLibrary™ mammalian display—enable the development of therapeutic lead antibodies against challenging targets such as CLDN18.2.

DiMPro^TM Nanodisc Membrane Protein Platforms

• Full-length GPCR proteins in native conformation
• Ion channel and multi-pass membrane protein solutions
• Stable and functional protein formats for drug discovery
• 700+ Nanodisc proteins, with 300+ in stock

Ready-to-Test Lead mAbs for Therapeutic Targets

• 5000+ Pre-validated IgG Sequences, 500+ Druggable Targets
• Zero Upfront, Zero Waiting, Zero Risk
• Functional Evaluation on Different Modality Platforms (CAR-T, ADC, BsAb, etc.)
• Mammalian Cell Display Based Antibody Engineering Platform for lead mAbs Optimization